Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions

Toxicon

Volumn 67, Issue , 2013, Pages 129-140

  Chancellor, Michael B ^a   Elovic, Elie ^b   Esquenazi, Alberto ^c   Naumann, Markus ^d   Segal, Karen R ^b   Schiavo, Giampietro ^e   Smith, Christopher P ^f   Ward, Anthony B ^g  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^b Moss Rehab and Albert Einstein Medical Center ^*  (United States)

^c ALBERT EINSTEIN MEDICAL CENTER   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g HAYWOOD HOSPITAL   (United Kingdom)

Author keywords

Benign prostatic hypertrophy; Botulinum neurotoxin; Botulinum toxin; Detrusor sphincter dyssynergia; Neurogenic bladder; Overactive bladder

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO;

CONSTIPATION; DETRUSOR DYSSYNERGIA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; HEMATURIA; HUMAN; MALAISE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATITIS; RESIDUAL URINE; REVIEW; STOMACH PARESIS; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE RETENTION; UROSEPSIS; WEAKNESS; XEROSTOMIA;

EID: 84877708124     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.01.020     Document Type: Review

References (23)

1. Abdel-Meguid T.A. Botulinum toxin-A injections into neurogenic overactive ladder-to include or exclude the trigone? A prospective, randomized, controlled trial. J. Urol. 2010, 184:2423-2428.
2. Apostolidis A., Dasgupta P., Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. 2006, 49:644-650.
3. Brubaker L., Richter H.E., Visco A., Mahajan S., Nygaard I., Braun T.M., Barber M.D., Menefee S., Schaffer J., Weber A.M., Wei J., Pelvic Floor Disorders N. Refractory idiopathic urge urinary incontinence and botulinum A injection. J. Urol. 2008, 180:217-222.
4. Cohen B.L., Barboglio P., Rodriguez D., Gousse A.E. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol. Urodyn. 2009, 28:205-208.
5. Crawford E.D., Hirst K., Kusek J.W., Donnell R.F., Kaplan S.A., McVary K.T., Mynderse L.A., Roehrborn C.G., Smith C.P., Bruskewitz R. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J. Urol. 2011, 186:965-970.
6. Cruz F., Herschorn S., Aliotta P., Brin M., Thompson C., Lam W., Daniell G., Heesakkers J., Haag-Molkenteller C. Efficacy and safety of OnabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur. Urol. 2011, 60:742-750.
7. de Seze M., Petit H., Gallien P., de Seze M.P., Joseph P.A., Mazaux J.M., Barat M. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol. 2002, 42:56-62.
8. Dmochowski R., Chapple C., Nitti V.W., Chancellor M., Everaert K., Thompson C., Daniell G., Zhou J., Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J. Urol. 2010, 184:2416-2422.
9. Dykstra D.D., Sidi A.A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch. Phys. Med. Rehabil. 1990, 71:24-26.
10. Ehren I., Volz D., Farrelly E., Berglund L., Brundin L., Hultling C., Lafolie P. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand. J. Urol. Nephrol. 2007, 41:335-340.
11. Gallien P., Reymann J.M., Amarenco G., Nicolas B., de Seze M., Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J. Neurol. Neurosurg. Psychiatry 2005, 76:1670-1676.
12. Ghei M., Maraj B.H., Miller R., Nathan S., O'Sullivan C., Fowler C.J., Shah P.J., Malone-Lee J. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J. Urol. 2005, 174:1873-1877. discussion 1877.
13. Giannantoni A., Di Stasi S.M., Stephen R.L., Bini V., Costantini E., Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J. Urol. 2004, 172:240-243.
14. Grise P., Ruffion A., Denys P., Egon G., Kastler E.C. Efficacy and tolerability of botulinum toxin type a in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Eur. Urol. 2010, 58:759-766.
15. Herschorn S., Gajewski J., Ethans K., Corcos J., Carlson K., Bailly G., Bard R., Valiquette L., Baverstock R., Carr L., Radomski S. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J. Urol. 2011, 185:2229-2235.
16. Kuo H.C., Liu H.T. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand. J. Urol. Nephrol. 2009, 43:206-211.
17. Maria G., Brisinda G., Civello I.M., Bentivoglio A.R., Sganga G., Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259-264.
18. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001, 87:760-766.
19. Naumann M., So Y., Argoff C.E., Childers M.K., Dykstra D.D., Gronseth G.S., Jabbari B., Kaufmann H.C., Schurch B., Silberstein S.D., Simpson D.M. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1707-1714.
20. Roehrborn C.G. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med. Clin. North. Am. 2011, 95:87-100.
21. Safari S., Jamali S., Habibollahi P., Arshadi H., Nejat F., Kajbafzadeh A.M. Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. Urology 2010, 76:225-230.
22. Sahai A., Khan M.S., Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 2007, 177:2231-2236.
23. Schurch B., De Seze M., Denys P., Chartier-Kastler E., Haab F., Everaert K., Plante P., Perrouin-Verbe B., Kumar C., Fraczek S., Brin M.F., Team B.D.H.S. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 2005, 174:196-200.